Prof. Dr. Götz Münch


Götz Münch is co-founder and managing director of advanceCOR GmbH, Martinsried, a Biotech company dedicated to the development of cardiovascular drugs. He was co-founder and managing director of Corimmun GmbH, which was successfully sold to Johnson & Johnson in 2012. Previously, he founded and managed ProCorde GmbH, where he was responsible for the site in Martinsried after successful merger with the English Biotech company TRIGEN (London, UK) from 2005.

After completion of his MD thesis at the Pharmacology Department of the University Freiburg at Prof. Dr. K. Starke and at the University College London at Prof. Dr. G. Burnstock in 1992, he made his PhD (Habilitation) in 2004 in Pharmacology at the University Würzburg. Since 2012 he is appointed assistant professor at the University of Würzburg.

He is consultant (Facharzt) for Internal Medicine and Cardiology and is lecturer in Biomedicine at the Julius-Maximilians-Universität Würzburg and teaches in the field of physiology/pathophysiology since 2001.
Götz is currently responsible for investor relations and the general funding and strategy of advanceCOR as Chief Executive officer. He is mainly responsible for the clinical development of the projects at advanceCOR. He planned and managed one phase I and two phase II multi-national studies as sponsor of the trial and in cooperation with an investigator-initiated study. He took the role of the Clinical Research Physician responsible for the design, preparation of the study including the approval with ethic committees and drug authorities and pharmacovigilance during the course of the study.